What Does Shorts Really Think About Agile Therapeutics, Inc. (AGRX)?

Agile Therapeutics, Inc. (NASDAQ:AGRX) short sellers believe it will rise in price. The most recent short interest data has been released for the January 31st settlement date, which shows a -80,316 share decrease in total short interest for AGRX, to 912,833, a retreat of 8.09% since January 15th. Average daily volume for Agile Therapeutics, Inc. at the January 31st settlement plunged to 185,370, as compared to 209,453 at the January 15th report. That brought days to cover to 4.924384, a 3.85% increase from the 4.741632 days to cover recorded at the prior short interest data release. You could look at analyst ratings. The average analyst recommendations at 2.3 suggests buying these shares. But the opinions of a small number of people, though sometimes influential, doesn’t always speak for the hundreds of thousands of traders on Wall Street.

Agile Therapeutics, Inc. (AGRX) will probably climb 170.27 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $4 price as 12-month high target. This represents a whopping 260.36 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $3, which represents a return potential of 170.27 percent when compared to the closing price of the stock of $1.11 on Wednesday, February 13. The lowest price target for the stock is $3 — slightly more than 170.27 percent from AGRX’s current share price.

The stock is currently hovering around the first support level of $1.02. Below this, the next support is placed in the zone of $0.93. Till the time, the AGRX stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 76.47 on daily chart, which may remain a cause for concern. If the price breaks below $0.93 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $1.19 mark may result into a pull-back move towards $1.27 level.

On 13th of February, Agile Therapeutics, Inc. (NASDAQ:AGRX) shares ended higher after a volatile session. The shares accumulated 0.12 points or 12.12 percent at $1.11 with a light trade volume of 2.641 million shares. After opening the session at $1.02, the shares went as high as $1.18 and as low as $1.01, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $38.16 million and now has 34.38 million shares outstanding. Agile Therapeutics, Inc. (AGRX) stock has gained 42.31 percent of market value in 21 trading days.

AGRX stock has a trailing 3-year beta of 0.34, offering the possibility of a lower rate of return, but also posing less risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$0.65 a share in the trailing twelve months. The stock’s value has surged 92.74 percent year to date (YTD) against a decline of -67.35 percent in 12 month’s time. The company’s shares still trade -71.68 percent away from its 1-year high of $3.92 and 380.52 percent up from 52-week low of $0.23. The average consensus rating on the company is 2.3, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a sell.

Shares of Agile Therapeutics, Inc. (AGRX) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry AGRX operates in has an average P/E of 69.44. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 0 on the Price-to-Sales ratio. Compare this with the industry average P/S of 49.51. 0 percent is the gross profit margin for Agile Therapeutics, Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.

Let’s take a look at some insider activity at Agile Therapeutics, Inc. (NASDAQ:AGRX) and see the pattern. The earliest insider trade took place on 07/26/2018. Perceptive Life Sciences Maste parted with a total of 298.63 thousand shares of company at average share price of $0.3. The total for the sales was set at $89.59 thousand. After this transaction, the account balance stood at 3.23 million shares. The stock grew 270 percent since that insider sale. On 08/25/2017, Altomari Alfred, Chairman & Chief Executive Off, purchased 10 thousand shares at a price per share of $3.34. This added 33.4 thousand shares to the insider’s fortune and the stock saw a -66.77 percent retreat in value since the news became public. This transaction left 161.59 thousand shares in the Chairman & Chief Executive Off account.

On 08/25/2017, Chief Commercial Officer Selman Renee performed a purchase transaction worth $24.29 thousand. This purchase at $3.35 each has added 7.25 thousand shares into the insider’s portfolio position. Meanwhile, shares have recorded -66.87 percent decrease since the transaction was reported. The insider now is left with 60.58 thousand shares remaining in the account. Altomari Alfred, who performs the Chairman and Chief Executive O job, bought 10 thousand shares for $35.1 thousand. The acquisition occurred on 05/11/2017 was priced at $3.51 per share. The share price plunged -68.38 percent since the reporting date. Altomari Alfred now left with a stake of 151.59 thousand AGRX stock worth $168.26 thousand after the insider buying.